-Advertisement-
-Advertisement-
Genetic and Congenital
Rett syndrome phase 3 trial meets primary, secondary efficacy endpoints
A once daily oral liquid dose of up to 30mg ANAVEX2-73 (blarcamesine) demonstrated statistically significant and clinically meaningful reductions in symptoms with related changes in potential biomarkers (GABA and L-AAA) of disease pathology improvement over placebo, in adult women with Rett syndrome, according to top-line results from the Phase 3...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved